4142:TPE
Adimmune Corp
17,00Â NT$
0,00%
(0,00) 1 p
4. nov, 13:30:11 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Turu kapit.
7,30Â mld
Keskm. maht
1,07Â mln
Maht
0,00
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Turu kapit.
7,30Â mld
Keskm. maht
1,07Â mln
Maht
0,00
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
AI Insider
·
28 minuti eest
Agility Robotics Completes SPAC Merger Ahead of Nasdaq Debut
Yahoo Finance
·
1 tunni eest
S&P 500, Nasdaq Surge Ahead After Democratic Sweep, Dow Jumps To One-Year High On Lower Oil — AAPL, SNAP, INTC, CRWV, QCOM In Focus
ChartMill
·
30 minuti eest
Prospect Capital (NASDAQ:PSEC) Posts Mixed Q1 as NII Beats, Revenue Misses, and Distribution Is Cut
Bloomberg.com
·
1 tunni eest
Asian Stocks to Rise as Oil Slides After US Vote: Markets Wrap
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta